Media ReleasesAntisense Therapeutics

View All Antisense Therapeutics News


Antisense Therapeutics Limited (ASX:ANP) ATL1103 - Additional US Patent Granted

ATL1103 - Additional US Patent Granted
 
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that on 7 December, 2010 the United States Patent Office granted US patent 7,846,906 covering ATL1103 entitled "Modulation of growth hormone receptor expression and insulin-like growth factor expression."
 
Consistent with the Company’s strategy to build comprehensive intellectual property protection for its product pipeline assets, this patent adds to the extensive patent position on ATL1103 and broader applications of antisense technology targeting the human growth hormone receptor. This includes US patent 7,803,781 issued September 28, 2010 that provides protection to early 2025 and a corresponding granted NZ patent. An Australian patent 2004217508 has also been allowed and will proceed to grant on 16 December this year. Related patents are under examination in other major markets.
 
These patents and patent applications provide important protection and strong commercial underpinning for the Company’s development of ATL1103 as a potential treatment for growth and sight disorders.
Download this document